Ignite Creation Date:
2025-12-24 @ 5:37 PM
Ignite Modification Date:
2026-02-25 @ 2:36 AM
Study NCT ID:
NCT06685068
Status:
RECRUITING
Last Update Posted:
2025-12-02
First Post:
2024-11-11
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Phase 1/2 Study of GEN1286 in Patients With Advanced Solid Tumors
Sponsor:
Genmab
Organization:
Study Overview
Official Title:
A Phase 1/2 Study of GEN1286 in Patients With Advanced Solid Tumors
Status:
RECRUITING
Status Verified Date:
2025-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this trial is to evaluate the safety, tolerability, pharmacokinetics (PK), anti-tumor activity and immunogenic potential of GEN1286 in participants with advanced solid tumors.
This trial consists of 2 parts:
* Part A: Dose escalation and dose level expansion
* Part B: Tumor-specific expansion with dose optimization
This trial consists of 2 parts:
* Part A: Dose escalation and dose level expansion
* Part B: Tumor-specific expansion with dose optimization
Detailed Description:
None
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: